Long‐term treatment with lansoprazole for patients with Zollinger–Ellison syndrome

  title={Long‐term treatment with lansoprazole for patients with Zollinger–Ellison syndrome},
  author={Basil I. Hirschowitz and Jean Mohnen and S. Shaw},
  journal={Alimentary Pharmacology \& Therapeutics},
Background: Normalization of gastric secretion and cure of associated upper gastrointestinal lesions by resection of gastrinoma is possible in ≈20% of patients with Zollinger–Ellison syndrome, leaving ≈80% dependent on medical treatment with proton pump inhibitors for acid suppression. 
Management of the Zollinger–Ellison syndrome in patients with multiple endocrine neoplasia type 1
  • Jensen
  • Medicine
    Journal of internal medicine
  • 1998
Management of the Zollinger–Ellison syndrome in patients with multiple endocrine neoplasia type 1 (Minisymposium: MEN & VHL).
Long‐term lansoprazole control of gastric acid and pepsin secretion in ZE and non‐ZE hypersecretors: a prospective 10‐year study
The majority of patients with Zollinger–Ellison syndrome require lifelong treatment with proton pump inhibitors.
Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long‐term treatment in ZE and non‐ZE acid hypersecretors
Helicobacter pylori infection may increase or decrease acid secretion and may augment proton pump inhibitor efficacy in Zollinger–Ellison syndrome (ZE) specifically.
Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
  • B. Hirschowitz, J. Simmons, J. Mohnen
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2005
Helicobacter pylori effects on gastritis, gastrin and enterochromaffin‐like cells in Zollinger–Ellison syndrome and non‐Zollinger–Ellison syndrome acid hypersecretors treated long‐term with lansoprazole
Helicobacter pylori is said to cause atrophy of the gastric corpus and enterochromaffin‐like cell proliferation in gastro‐oesophageal reflux disease (GERD) patients treated long‐term with a proton
Zollinger-Ellison Syndrome Successfully Treated with Esomeprazole
Treatment with esomeprazole relieved the diarrhea, nausea and vomiting associated with ZES when prescribed at 40 mg twice daily and should be studied further to determine its efficacy and optimal dosing for this difficult-to-treat patient population.
Optimal Treatment of Zollinger-Ellison Syndrome and Related Conditions in Elderly Patients
The treatment of elderly Zollinger-Ellison syndrome patients, similarly to all elderly oncological patients, should be based on the use of comprehensive geriatric assessment, to decide whether the patient can tolerate surgery and/or the stress of antineoplastic therapy, and whether the only possible choice is palliative relief of symptoms.
Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
The insights from studies on ZES into these controversial issues with pertinence to chronic PPI use in non-ZES patients is reviewed, primarily concentrating on data from the prospective long-term studies of ZES patients at NIH.
Evaluation of new diagnostic and treatment strategies in the management of the Zollinger-Ellison syndrome
A database of 40 ZES patients treated at Groote Schuur Hospital over two decades is analyzed to investigate a possible correlation between biological tissue marker expression and tumour behaviour and assess the efficacy and safety of a new proton pump inhibitor (pantoprazole) in controlling acid hypersecretion.


Use of omeprazole in Zollinger‐Ellison syndrome: a prospective nine‐year study of efficacy and safety
It is concluded that omeprazole effectively and safely controls gastric acid hypersecretion in all patients with Zollinger‐Ellison syndrome for up to nine years without evidence by tachyphylaxis.
Treatment of patients with Zollinger-Ellison syndrome.
It is indicated that lansoprazole is an efficacious, well-tolerated antisecretory agent in patients with Zollinger-Ellison syndrome.
[Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
Data proved that lansoprazole is efficient for treating gastric acid hypersecretion in patients suffering from ZES, with a rapid relief of clinical symptoms.
Prospective study of the need for long‐term antisecretory therapy in patients with Zollinger—Ellison syndrome following successful curative gastrinoma resection
It is concluded that following successful curative gastrinoma resection, 40% of patients still require antisecretory therapy and that both symptom evaluation as well as upper endoscopy should be used to guide attempted drug withdrawal.
The Role of Surgery in the Zollinger‐Ellison Syndrome
Treatment of the hypersecretory problems of the Zollinger-Ellison syndrome by total gastrectomy is safe and dependable, and results compare well with those of long-term medical management, whose success is dependent upon serial favorable responses to a lifetime of repeated challenges.
Early surgical treatment of gastrinoma.